Evaluation of PMEA efficacy in macaques chronically infected with simian immunodeficiency virus (SIV).

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Evaluation of PMEA efficacy in macaques chronically infected with simian immunodeficiency virus (SIV).

Symp Nonhum Primate Models AIDS. 1993 Sep 19-22;11:abstract no. 101. Unique Identifier : AIDSLINE PRIM11/94191597
Follis KE; Tsai CC; Grant R; Sabo A; Bischofberger N; University of Washington Primate Research Center, Seattle.

Abstract: Macaque monkeys infected with SIV can be utilized for preclinical evaluation of antiretroviral drugs/compounds. For this study we used 10 Macaca fascicularis which had been chronically infected with SIVmne for over 11 months to test 9-(-2-phosphonylmethoxyethyl)adenine (PMEA). PMEA was previously shown to inhibit in vitro replication of SIV and human immunodeficiency viruses (HIV-1 and HIV-2). Three macaques received a subcutaneous dose of 30 mg/kg PMEA once daily and seven macaques received a subcutaneous dose of 20 mg/kg PMEA once daily for one month. The 10 virus-positive macaques became virus-negative during PMEA treatment as determined by cocultures of peripheral blood mononuclear cells (PBMC). One macaque tested positive at the end of the 4-week treatment regimen. Two weeks after PMEA-treatment stopped, all 10 macaques were virus positive but showed reduced titers of virus load in the blood. Throughout treatment, all macaques showed positive PCR for SIV DNA in PBMCs. We found that PMEA was effective as a single-therapeutic agent against chronic SIV infection during the 4-week therapy regimen. Future studies using alternative or combination therapy with PMEA may prove to be more beneficial for long-term antiretroviral efficacy.

Keywords: Adenine/*ANALOGS & DERIVATIVES/TOXICITY/THERAPEUTIC USE Animal Antiviral Agents/TOXICITY/*THERAPEUTIC USE Drug Administration Schedule Drug Evaluation/METHODS DNA, Viral/ANALYSIS HIV-1/DRUG EFFECTS/PHYSIOLOGY HIV-2/DRUG EFFECTS/PHYSIOLOGY Lymphocytes/MICROBIOLOGY Macaca fascicularis Polymerase Chain Reaction Simian Acquired Immunodeficiency Syndrome/*DRUG THERAPY SIV/DRUG EFFECTS/PHYSIOLOGY Time Factors Virus Replication/DRUG EFFECTS ABSTRACT
940730
M9470921

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .